secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001193125-26-018664
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics exchanges 2.5M common shares for Series A convertible preferred with Blue Owl
--------------------------------------------------------------------------------

- Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares (10:1 conversion ratio).
- Series A preferred has no voting rights except as required by law and ranks pari passu with common on liquidation.
- Certificate of Amendment increased authorized Series A preferred from 250,000 to 500,000 shares.
- Exchange expected to close Jan 23, 2026, exempt from registration under Section 3(a)(9) of the Securities Act.
- Preferred shares are convertible into up to 2.5M common shares, subject to beneficial ownership limitations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526018664/0001193125-26-018664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526018664/d27699d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-018664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer